NCT00484848

Brief Summary

Totally implanted venous access ports allow a safe delivery of medication, mainly chemotherapy, but are also used for blood sampling. This last procedure is not always successful, as it appeared from a nurse's survey in different hospitals in Flanders, including the University Hospitals in Leuven, Belgium. In 3 to 29 percent of the attempts, blood withdrawal is impaired or not possible, as an intermittent or permanent fact. This is in line with international literature data where difficulty in blood draw was noted in 6 to 26% of port accessions. Partial or total occlusion leads to discomfort for the patient, delay in therapy, higher costs and extra nursing time. A new port system with a tangential outlet (Vortex port) was designed and according to the manufacturer, this shape will allow to cleanse the entire reservoir of the port more efficiently and avoid the formation of precipitates of medication or blood that could lead to an obstruction of the device. These precipitates are also regarded as a potential risk factor for infection. However, only one previously published small randomised study addressed the value of the Vortex port when compared to conventional access devices: Stevens et al. were able to show a reduction in obstruction incidence from 26% to 7% with the use of the Vortex port. The incidence of blood withdrawal problems in our experience with conventional ports in University hospitals Leuven was 8% thus lower than that reported by Stevens, but this remains the most frequent problem faced by care providers and patients. With this study, the investigators aim to compare the performance of the tangential outlet ports and that of a "conventional" port in order to assess an eventual functional difference.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2004

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2004

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2004

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2005

Completed
2.3 years until next milestone

First Submitted

Initial submission to the registry

June 7, 2007

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 11, 2007

Completed
Last Updated

January 26, 2009

Status Verified

January 1, 2009

Enrollment Period

3 months

First QC Date

June 7, 2007

Last Update Submit

January 23, 2009

Conditions

Keywords

oncology, medicalimplantable cathetervascular access portspersistent withdrawal occlusionVortex®Celsite®Vacutainer®venous cut-down

Outcome Measures

Primary Outcomes (3)

  • Evaluation of the difference in difficulty in blood drawing between the 2 types of ports when accessing the port under identical maintenance procedure according to the guidelines in the University Hospitals Leuven.

    up to a maximum of 6 months after insertion

  • Evaluation of the difference in one-way or bidirectional occlusion incidence between these 2 types of ports, when accessing the port under identical maintenance procedure according to the guidelines in the University Hospitals Leuven.

    up to a maximum of 6 months after insertion

  • Evaluation of the difference in filling time for blood sampling between these 2 types of ports when using a standard 10 ml vacuum blood tube and a 19 G Gripper® needle.

    immediately after insertion and up to a maximum of 6 months afterwards

Secondary Outcomes (1)

  • Evaluation of the ease of use (ease of access) between these 2 types of ports when accessing the port.

    up to a maximum of 6 months after insertion

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • request of a standard size totally implanted venous port
  • patent superior vena cava
  • normal clotting tests (PT\>40% and platelet count \>40000/mm3)

You may not qualify if:

  • unable to provide written informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospitals Leuven

Leuven, 3000, Belgium

Location

Related Publications (3)

  • Stevens B, Barton SE, Brechbill M, Moenter S, Piel AL, Shankle D. A Randomized, Prospective Trial of Conventional Vascular Ports Vs.the Vortex

    BACKGROUND
  • Lamont JP, McCarty TM, Stephens JS, Smith BA, Carlo J, Livingston S, Kuhn JA. A randomized trial of valved vs nonvalved implantable ports for vascular access. Proc (Bayl Univ Med Cent). 2003 Oct;16(4):384-7. doi: 10.1080/08998280.2003.11927932.

    PMID: 16278752BACKGROUND
  • Goossens GA, Verbeeck G, Moons P, Sermeus W, De Wever I, Stas M. Functional evaluation of conventional 'Celsite' venous ports versus 'Vortex' ports with a tangential outlet: a prospective randomised pilot study. Support Care Cancer. 2008 Dec;16(12):1367-74. doi: 10.1007/s00520-008-0436-y. Epub 2008 Apr 15.

MeSH Terms

Conditions

Hematologic DiseasesNeoplasms

Condition Hierarchy (Ancestors)

Hemic and Lymphatic Diseases

Study Officials

  • Marguerite Stas, MD PhD

    KU Leuven

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
CARE PROVIDER
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

June 7, 2007

First Posted

June 11, 2007

Study Start

September 1, 2004

Primary Completion

December 1, 2004

Study Completion

March 1, 2005

Last Updated

January 26, 2009

Record last verified: 2009-01

Locations